RecruitingNCT06480591
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Sponsor
Wake Forest University Health Sciences
Enrollment
35 participants
Start Date
Jan 21, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
- Age ≥ 18 years at the time of enrollment
- Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
- CALR-positive genetic mutation
Exclusion Criteria1
- \- Diagnosis of MPN with JAK2 V617F mutation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERBlood Draw
The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06480591
Related Trials
Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities
NCT057145921 location
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT044931641 location
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
NCT035897291 location
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT0377985410 locations
Project: Every Child for Younger Patients With Cancer
NCT02402244278 locations